Status:
COMPLETED
Nalbuphine, Fentanyl and no Additive to Local Anaesthetic Mixture
Lead Sponsor:
Cairo University
Conditions:
Nalbuphine,Fentanyl and Local Anesthetic Mixture
Eligibility:
All Genders
40-70 years
Phase:
PHASE4
Brief Summary
Nalbuphine has been used as an adjuvant to bupivacaine in intrathecal,epidural, caudal anesthesia and peripheral nerve blocks showing an increase in the efficacy and the duration of postoperative anal...
Detailed Description
120 patients (40 in each group) scheduled for elective posterior chamber surgery using peribulbar block. Patients of Group N received 6 ml of 0.5% bupivacaine 1 ml hyaluronidase (75 IU), and 4mg of Na...
Eligibility Criteria
Inclusion
- patients aged 40-70 years.
- both sex.
- ASA physical status Ι\&II.
- Patient with axial globe length below 26
Exclusion
- Refusal of the patient to participate in the study.
- Coagulation abnormalities(INR\>1.4).
- More than ASA II.
- High myopia with axial length more than 26 mm.
- Mentally retarded patients and failure of proper communication as in deafness .
- Morbidly obese patients(BMI\>35)
- Patients with glaucoma (increased IOP\>20mmgh)
- Patients with history of hypersensitivity to study drugs
Key Trial Info
Start Date :
February 5 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 18 2019
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT03824665
Start Date
February 5 2019
End Date
May 18 2019
Last Update
May 21 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ahmed Abdalla Mohamed
Cairo, Egypt, 11451